Status:
COMPLETED
Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Abbott Medical Devices
Conditions:
Cardiac Allograft Vasculopathy
Eligibility:
All Genders
18+ years
Brief Summary
Cardiac allograft vasculopathy (CAV) is a progressive disease of the coronary arteries in transplanted hearts which is a significant cause of morbidity and mortality. The broad objective of this resea...
Eligibility Criteria
Inclusion
- patients aged 18 or older
- patients with cardiac transplant undergoing routine CAV surveillance
Exclusion
- patients \< 18 years old
- patients with acute rejection
- patients with active infection
- patients with chronic renal insufficiency with a glomerular filtration rate (GFR) \< 30ml/min
- patients not able to give informed consent
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT01527344
Start Date
August 1 2011
End Date
August 1 2013
Last Update
May 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905